Cycrimine is an orally active muscarinic cholinergic receptor (mAChR) M1 antagonist, reduces the acetylcholine levels in parkinson model. Cycrimine shows antispasmodic activity, can be used in studies of behavioral and mental disorder.
References:
[1]. David T. CHAU. Methods of treating behaviorial and/or mental disorders. WO2014176460A1. [2]. Marzoughi S, et al. Tardive neurotoxicity of anticholinergic drugs: A review. J Neurochem. 2021 Sep;158(6):1334-1344.
[3]. Tacke, et al. Syntheses and pharmacological characterization of achiral and chiral enantiopure C/Si/Ge-analogous derivatives of the muscarinic antagonist cycrimine: a study on C/Si/Ge bioisosterism. Journal of organometallic chemistry 640.1-2 (2001): 140- [4]. MAGEE KR, et al. Antispasmodic compound 08958 in treatment of paralysis agitans. J Am Med Assoc. 1953 Oct 24;153(8):715-8.